Bristol-Myers Squibb Reports Second Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Bristol-Myers Squibb Co. (BMY) PT Lowered to $61 at Leerink Partners
July 28, 2017 10:31 AM EDTLeerink Partners lowered its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $61.00 (from $66.00) while maintaining a Outperform rating following the company's 2Q. BMY delivered in line earnings of 74c.
Analyst Seamus Fernandez now forecasts a 9% EPS growth in 2018-22E excluding Opdivo +... More
Bristol-Myers Squibb (BMY) Reports In-Line Q2 EPS, Updates FY EPS Guidance
July 27, 2017 7:01 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $0.74, in-line with the analyst estimate of $0.74. Revenue for the quarter came in at $5.14 billion versus the consensus estimate of $5.09 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2017 EPS of $2.90-$3.00, versus the consensus of... More
